LLY

722.13

-3.25%↓

JNJ

146.57

-1.49%↓

UNH

312.79

-2.04%↓

ABBV

179.89

-4.64%↓

NVO

64.75

-0.87%↓

LLY

722.13

-3.25%↓

JNJ

146.57

-1.49%↓

UNH

312.79

-2.04%↓

ABBV

179.89

-4.64%↓

NVO

64.75

-0.87%↓

LLY

722.13

-3.25%↓

JNJ

146.57

-1.49%↓

UNH

312.79

-2.04%↓

ABBV

179.89

-4.64%↓

NVO

64.75

-0.87%↓

LLY

722.13

-3.25%↓

JNJ

146.57

-1.49%↓

UNH

312.79

-2.04%↓

ABBV

179.89

-4.64%↓

NVO

64.75

-0.87%↓

LLY

722.13

-3.25%↓

JNJ

146.57

-1.49%↓

UNH

312.79

-2.04%↓

ABBV

179.89

-4.64%↓

NVO

64.75

-0.87%↓

Search

Verve Therapeutics Inc

Atidarymo kaina

4.27 4.4

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

4.06

Max

5.03

Pagrindiniai rodikliai

By Trading Economics

Pajamos

98K

-50M

Pardavimai

6.2M

13M

Pelnas, tenkantis vienai akcijai

-0.58

Pelno marža

-382.531

Darbuotojai

274

EBITDA

789K

-54M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+480.46% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-15

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-133M

463M

Ankstesnė atidarymo kaina

-0.13

Ankstesnė uždarymo kaina

4.27

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Verve Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-13 23:20; UTC

Uždarbis

Aristocrat Leisure Boosts Half-Year Dividend, Keeps Focus on M&A

2025-05-13 23:48; UTC

Rinkos pokalbiai

Gold Edges Higher, Supported by Signs of Mild U.S. Inflation -- Market Talk

2025-05-13 23:43; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-05-13 23:43; UTC

Rinkos pokalbiai

Nikkei May Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

2025-05-13 23:24; UTC

Rinkos pokalbiai
Uždarbis

Global Equities Roundup: Market Talk

2025-05-13 23:24; UTC

Rinkos pokalbiai
Uždarbis

Aristocrat's 1H Result Falls Short, Jefferies Says -- Market Talk

2025-05-13 22:58; UTC

Uždarbis

Table: Samsung Fire & Marine 1Q Consolidated Net KRW609.03B Vs KRW701.95B

2025-05-13 22:58; UTC

Uždarbis

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Net KRW609.03B Vs KRW701.95B

2025-05-13 22:58; UTC

Uždarbis

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Op Pft KRW792.36B Vs Op KRW897.06B

2025-05-13 22:58; UTC

Uždarbis

Samsung Fire & Marine Insurance Co. Ltd. 1Q Consolidated Rev KRW6.106T Vs KRW5.507T

2025-05-13 22:38; UTC

Uždarbis

Aristocrat: Continues to Actively Pursue Strategic M&A Activities

2025-05-13 22:38; UTC

Uždarbis

Aristocrat: Remains Committed to Capital Management Strategy, Ongoing Share Buy-Back Program

2025-05-13 22:37; UTC

Uždarbis

Aristocrat: Expects More Operating Momentum in 2H Amid Product Rollout, Technology Initiatives

2025-05-13 22:36; UTC

Uždarbis

Aristocrat: Sees Accelerating Performance at Interactive Unit Toward FY 2029 US$1 Bln Revenue Target

2025-05-13 22:35; UTC

Uždarbis

Aristocrat: Expects Continued Market Share Gains from Gaming Unit

2025-05-13 22:34; UTC

Uždarbis

Aristocrat: Expects to Deliver NPATA Growth Over the Full Year on a Constant Currency Basis

2025-05-13 22:33; UTC

Uždarbis

Aristocrat: Interactive Business Delivered Strong Revenue Growth

2025-05-13 22:33; UTC

Uždarbis

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

2025-05-13 22:33; UTC

Uždarbis

Aristocrat: Product Madness' Key Social Casino Franchises Continued to Outperform

2025-05-13 22:30; UTC

Uždarbis

Aristocrat Interim Dividend 44 Australian Cents/Share

2025-05-13 22:30; UTC

Uždarbis

Aristocrat 1H Statutory Net Profit from Continuing Operations A$511 Mln, Down 21.6%

2025-05-13 22:29; UTC

Uždarbis

Aristocrat 1H Normalized Operating Revenue A$3 Bln, Up 8.7%

2025-05-13 22:28; UTC

Uždarbis

Aristocrat 1H Normalized Net Profit A$733 Mln, Up 5.6%

2025-05-13 21:15; UTC

Uždarbis

Nu Holdings 1Q Rev $3.2B >NU

2025-05-13 21:03; UTC

Svarbiausios naujienos

GOP Mega Bill's Details Are Out. Now the Fighting Begins. -- WSJ

2025-05-13 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-05-13 20:32; UTC

Uždarbis

Alcon Raises 2025 View To Sales $10.4B-$10.5B >ALC.EB

2025-05-13 20:31; UTC

Uždarbis

Alcon 1Q Sales $2.45B >ALC.EB

2025-05-13 20:30; UTC

Uždarbis

Alcon 1Q Rev $2.47B >ALC.EB

2025-05-13 20:30; UTC

Uždarbis

Alcon 1Q EPS 70c >ALC.EB

Akcijų palyginimas

Kainos pokytis

Verve Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

480.46% į viršų

12 mėnesių prognozė

Vidutinis 25.25 USD  480.46%

Aukščiausias 39 USD

Žemiausias 15 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Verve Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

9

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

4.1501 / 5.16Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Very Strong Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Verve Therapeutics Inc

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.